Valuation Neurogene Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
17.23 ^USD	+5.25%		-2.43%	-16.36%

02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2023	2024	2025	2026	2027
Capitalization ¹	248.5	339.6	266.9	266.9	-
Change	-	36.64%	-21.41%	0%	-
Enterprise Value (EV) ¹	51.47	27.17	32.09	-60.91	266.9
Change	-	-47.21%	18.09%	-289.82%	538.16%
P/E ratio	-2.49x	-5.34x	-4.03x	-3.44x	-3.1x
PBR	-	-	-	-	-
PEG	0.1x	0.1x	120.62x	-0.2x	-0.3x
Capitalization / Revenue	-	367x	-	-	-
EV / Revenue	-	29.4x	-	-	-
EV / EBITDA	-	-	-	-	-
EV / EBIT	-0.93x	-0.33x	-0.31x	0.52x	-2.02x
EV / FCF	-0.99x	-0.38x	-0.36x	0.59x	-2.44x
FCF Yield	-101%	-263%	-279%	170%	-41%
Dividend per Share ²	-	-	-	-	-
Rate of return	-	-	-	-	-
EPS ²	-7.798	-4.28	-4.279	-5.007	-5.56
Distribution rate	-	-	-	-	-
Net sales ¹	-	0.925	-	-	-
EBITDA	-	-	-	-	-
EBIT ¹	-55.58	-82.6	-103.4	-117.8	-132.3
Net income ¹	-36.32	-75.14	-91.05	-113.5	-128.7
Net Debt ¹	-197	-312.4	-234.8	-327.8	-
Reference price ²	19.38	22.86	17.23	17.23	17.23
Nbr of stocks (in thousands)	12,824	14,855	15,490	15,490	-
Announcement Date	18/03/24	24/03/25	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
NEUROGENE INC.	-4.03x	-	-	-	267M
LONZA GROUP AG	36.2x	5.26x	17.62x	0.95%	46.82B
BEONE MEDICINES AG	108.48x	6.96x	69.61x	-.--%	39.16B
CELLTRION, INC.	58.42x	11.94x	33.41x	0.33%	32.9B
IQVIA HOLDINGS INC.	26.51x	2.79x	11.94x	-.--%	31.8B
REVOLUTION MEDICINES, INC.	-17.45x	4983.42x	-16.28x	-.--%	18.85B
MEDPACE HOLDINGS, INC.	36.62x	5.92x	26.9x	-.--%	15.27B
Average	34.96x	836.05x	23.87x	0.21%	26.44B
Weighted average by Cap.	48.29x	514.15x	27.78x	0.3%